TP53 and cancer: Inhibition of this mitophagy pathway by a hypoxia-targeting p53 fusion protein, consisting of p53, TAT, and HIF-1α minimum oxygen-dependent degradation domain, sensitizes cancer cells in response to radiotherapy both in vitro and in vivo (Zheng et al., 2015).